라미부딘 내성을 보인 HBe 항원 음성 만성 B형간염 환자에서 페그인터페론 알파 치료 1예
A case report of treatment with pegylated interferon alpha for lamivudine-resistant chronic hepatitis B virus infection
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The wide use of lamivudine in chronic hepatitis B has produced a monotonic increase in patients with lamivudine resistance. Therefore, treating lamivudine resistance in chronic hepatitis B is a major concern in clinical practice for the treatment of hepatitis B virus (HBV). There is conflicting evidence on the outcome of pegylated interferon alpha (PEG-IFN α) therapy against lamivudine-resistant HBV, which is due to mutations in the YMDD motif. We experienced a patient with chronic hepatitis B who was successfully treated with PEG- IFN α-2a after the development of virologic and biochemical breakthrough during lamivudine therapy. Virologic breakthrough was associated with the emergence of YMDD mutants 48 months after starting lamivudine therapy. Treatment with PEG-IFN α-2a for 12 months resulted in an undetectable serum level of HBV DNA and the resolution of hepatitis, and the virologic response was maintained over 16 months after cessation of PEG-IFN α-2a.
Abstract
The wide use of lamivudine in chronic hepatitis B has produced a monotonic increase in patients with lamivudine resistance. Therefore, treating lamivudine resistance in chronic hepatitis B is a major concern in clinical practice for the treatment of hepatitis B virus (HBV). There is conflicting evidence on the outcome of pegylated interferon alpha (PEG-IFN α) therapy against lamivudine-resistant HBV, which is due to mutations in the YMDD motif. We experienced a patient with chronic hepatitis B who was successfully treated with PEG- IFN α-2a after the development of virologic and biochemical breakthrough during lamivudine therapy. Virologic breakthrough was associated with the emergence of YMDD mutants 48 months after starting lamivudine therapy. Treatment with PEG-IFN α-2a for 12 months resulted in an undetectable serum level of HBV DNA and the resolution of hepatitis, and the virologic response was maintained over 16 months after cessation of PEG-IFN α-2a.
참고문헌 (15)
- Liaw YF, "Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B", Gastroenterology, 119, pp.172~180 (2000)
- Leung NW, "Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy", Hepatology, 33, pp.1527~1532 (2001)
- Cooksley WG, "Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen- positive chronic hepatitis B", J Viral Hepat, 10, pp.298~305 (2003)
- Suzuki F, "Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy", J Gastroenterol, 37, pp.922~927 (2002)
- Lau GK, "Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B", N Engl J Med, 352, pp.2682~2695 (2005)
- Janssen HL, "Pegylated interferon alfa- 2b alone or in combination with lamivudine for HBeAg- positive chronic hepatitis B: a randomised trial", Lancet, 365, pp.123~129 (2005)
- Chan HL, "A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone", Ann Intern Med, 142, pp.240~250 (2005)
- Marcellin P, "Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg- negative chronic hepatitis B", N Engl J Med, 351, pp.1206~1217 (2004)
- Honkoop P, "Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns", J Hepatol, 26, pp.1393~1395 (1997)
- Allen MI, "Identification and characterization of mutations in hepatitis B virus resistant to lamivudine", Hepatology, 27, pp.1670~1677 (1998)
- Papatheodoridis GV, "Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance", Am J Gastroenterol, 97, pp.1618~1628 (2002)
- Liaw YF, "Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy", Hepatology, 30, pp.567~572 (1999)
- Leemans WF, "The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection", J hepatol, 44, pp.507~511 (2006)
- Vassiliadis T, "Pegylated IFN-α 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B", World J Gastroenterol, 12, pp.2417~2422 (2006)
- Shi M, "Sequential treatment with lamivudine and interferon- alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations", J Antimicrob Chemother, 58, pp.1031~1035 (2006)